The management of autoimmune liver diseases: from the consensus to the guideline
Xiong Ma
Published 2016-01-20
Cite as Chin J Hepatol, 2016, 24(1): 3-4. DOI: 10.3760/cma.j.issn.1007-3418.2016.01.003
Abstract
Autoimmune liver disease is an aberrant autoimmunity-mediated liver injury, its early diagnosis and management can significantly improve the prognosis of patients and their quality of life. Most recently, the 3 societies of Hepatology, Gastroenterology and Infectious Diseases of the Chinese Medical Association jointly released 4 consensuses about the diagnosis and management of autoimmune liver diseases. This academic milestone in the Chinese hepatology field should have major impact on the standardization and improvement of autoimmune liver disease management in China. We urgently need to carry out the joint clinical studies, in particular, multicenter randomized control prospective trials, to clarify the clinical and pathological features of Chinese patients with autoimmune liver diseases. We hope more and more original findings in China may promote the transition from the consensuses to guidelines in the near future.
Key words:
Hepatitis, autoimmune; Primary biliary cholangitis; Primary sclerosing cholangitis; Diagnosis; Therapy; Consensus
Contributor Information
Xiong Ma
Department of Gastroenterology, Renji Hospital, Shanghai JiaoTong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai 200127, China